Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026
Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026
Company Deals

Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round

Fineline Cube Jul 3, 2023

Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised...

Company Drug

Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China

Fineline Cube Jul 3, 2023

Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...

Company Drug

SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment

Fineline Cube Jul 3, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis

Fineline Cube Jul 3, 2023

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...

Company Drug

InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection

Fineline Cube Jul 3, 2023

InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...

Company Drug

Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer

Fineline Cube Jul 3, 2023

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study

Fineline Cube Jul 3, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China

Fineline Cube Jul 3, 2023

The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a...

Company Drug

Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis

Fineline Cube Jul 3, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...

Company Medical Device

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Fineline Cube Jul 3, 2023

China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...

Company Deals

Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence

Fineline Cube Jul 3, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Deals

Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1

Fineline Cube Jul 3, 2023

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...

Company Drug

ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study

Fineline Cube Jul 3, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...

Company Drug

Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment

Fineline Cube Jul 3, 2023

The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...

Company Drug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...

Company Deals

Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development

Fineline Cube Jun 30, 2023

Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...

Company Drug

Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 30, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update

Fineline Cube Jun 30, 2023

The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...

Company Drug

Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection

Fineline Cube Jun 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 545 546 547 … 703

Recent updates

  • AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
  • WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
  • Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
  • Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
  • CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.